Azithromycin and early allograft function after lung transplantation: A randomized, controlled trial

Area of Science:

• Pulmonology
• Transplantation Medicine
• Pharmacology

Background:

• Chronic lung allograft dysfunction (CLAD) is a primary limitation to long-term survival after lung transplantation (LTx).
• Azithromycin has demonstrated benefits in improving CLAD-free and long-term survival post-LTx.
• The impact of azithromycin on early lung allograft function remains unclear.

Purpose of the Study:

• To evaluate the effect of pre-transplant and prompt post-transplant azithromycin on early lung allograft function.
• To assess secondary outcomes including airway inflammation, rejection, infection, and survival rates.

Main Methods:

• A prospective, randomized, double-blind, placebo-controlled trial involving 68 patients undergoing LTx.
• Azithromycin or placebo administered pre-transplant and daily for 31 days post-transplant.
• Primary outcome: 15% improvement in FEV1 within 3 months post-LTx; secondary outcomes included inflammation markers and survival.

Main Results:

• No significant difference in FEV1 between azithromycin and placebo groups at 3 months post-LTx (p=0.41).
• Azithromycin group showed reduced airway inflammation, evidenced by lower bronchoalveolar lavage (BAL) neutrophilia and IL-8 levels at Days 30 and 90.
• No significant differences observed in other secondary outcomes between the groups.

Conclusions:

• Pre- and post-transplant azithromycin did not enhance early lung allograft function.
• The study confirmed the anti-inflammatory properties of azithromycin in the context of LTx.
• Further research may explore alternative azithromycin regimens or patient populations for potential benefits.